NERV · Minerva Neurosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.25M | - | $925.4K | $1.30M | $1.36M | - | $1.89M | $3.86M | $4.17M | - |
| SG&A | $11.42M | - | $1.92M | $2.08M | $2.54M | - | $2.48M | $2.42M | $2.51M | - |
| Total Operating Expenses | $16.67M | - | $2.84M | $3.37M | $3.90M | - | $4.37M | $6.28M | $6.68M | - |
| D&A | - | - | - | - | $1.4K | - | - | - | $1.4K | - |
| Operating Income | ($16.67M) | - | ($2.84M) | ($3.37M) | ($3.90M) | - | ($4.37M) | ($6.28M) | ($6.68M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($125.40M) | - | ($2.74M) | ($3.26M) | ($3.75M) | - | $22.51M | ($8.23M) | ($8.57M) | - |
| EPS - Basic | ($2.86) | - | ($0.36) | ($0.43) | ($0.50) | - | $2.97 | ($1.09) | ($1.13) | - |
| EPS - Diluted | ($2.86) | - | ($0.36) | ($0.43) | ($0.50) | - | $2.97 | ($1.09) | ($1.13) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.66M | $82.30M | $12.29M | $15.25M | $17.29M | $21.36M | $26.53M | $30.88M | $34.82M | $40.91M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.12M | $639.7K | $944.5K | $896.8K | $639.9K | $1.61M | $553.2K | $828.3K | $1.44M | $1.81M |
| Current Assets | $79.11M | $83.10M | $13.02M | $15.55M | $17.92M | $22.27M | $27.94M | $31.41M | $35.62M | $42.00M |
| Total Assets | $94.03M | $97.97M | $28.09M | $30.42M | $32.80M | $37.14M | $42.81M | $46.29M | $50.51M | $56.90M |
| Current Liabilities | $4.48M | $2.29M | $2.67M | $2.53M | $1.95M | $2.84M | $4.48M | $4.20M | $2.83M | $3.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $343.08M | $233.76M | $62.67M | $62.53M | $61.95M | $62.84M | $64.48M | $90.78M | $87.10M | $85.36M |
| Stockholders' Equity | ($254.01M) | ($140.75M) | ($34.58M) | ($32.11M) | ($29.15M) | ($25.69M) | ($21.67M) | ($44.49M) | ($36.59M) | ($28.46M) |
| Retained Earnings | ($814.20M) | ($688.80M) | ($405.13M) | ($402.39M) | ($399.13M) | ($395.38M) | ($391.10M) | ($413.62M) | ($405.38M) | ($396.82M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.43M) | - | - | - | ($4.07M) | - | - | - | ($6.09M) | - |
| Investing Cash Flow | ($45.29M) | - | - | - | $0 | - | - | - | $0 | - |
| Financing Cash Flow | $1.08M | - | - | - | $0 | - | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -133.4% | - | -9.8% | -10.7% | -11.4% | - | 52.6% | -17.8% | -17.0% | - |
| Return on equity | 49.4% | - | 7.9% | 10.1% | 12.9% | - | -103.9% | 18.5% | 23.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 17.65 | 36.28 | 4.87 | 6.15 | 9.21 | 7.85 | 6.23 | 7.47 | 12.58 | 12.57 |
| Quick ratio | 17.65 | 36.28 | 4.87 | 6.15 | 9.21 | 7.85 | 6.23 | 7.47 | 12.58 | 12.57 |
| Cash ratio | 7.29 | 35.93 | 4.60 | 6.03 | 8.88 | 7.53 | 5.92 | 7.35 | 12.30 | 12.25 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.37 | -0.70 | -0.81 | -0.95 | -1.13 | -1.45 | -1.98 | -1.04 | -1.38 | -2.00 |
| Liabilities / Assets | 3.65 | 2.39 | 2.23 | 2.06 | 1.89 | 1.69 | 1.51 | 1.96 | 1.72 | 1.50 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 0.9x | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -327.2% | - | 34.9% | 46.3% | 41.6% | - | 28.2% | -38.9% | -24.9% | - |
| Net income growth (YoY) | -3241.5% | - | - | 60.4% | 56.2% | - | - | -33.0% | -22.9% | - |
| EPS growth (YoY) | -472.0% | - | - | 60.6% | 55.8% | - | - | 33.1% | 38.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -771.4% | -447.8% | -59.6% | 27.8% | 20.3% | 9.7% | -8.1% | -255.6% | -37.5% | -42.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Minerva Neurosciences against the 5 most active filers in the same SIC group.